page header

Contents  ·  Introduction  ·  Learning  Objectives  ·  Textbook  ·  Lectures  ·  Procedures  ·  Final Exam  ·  Library  ·  Laboratory  ·  Pharmacy  ·  Imaging  ·  Forms  ·  Videos  ·  About  ·  Contact Us>

DITROPAN XL® (Ortho-McNeil) (oxybutynin chloride)

Category:

  • Antispasmodic, anticholinergic

Description:

  • Relaxes bladder smooth muscle

Indications:

  • Irritable bladder

  • Urgency incontinence

Contraindications:

  • Urinary retention
  • Gastric retention and other severe decreased gastrointestinal motility condition
  • Uncontrolled narrow-angle glaucoma and in patients who are at risk for these conditions.
  •  hypersensitivity to the medication

Precautions:

  • Pregnancy category B

  • Used with caution in patients with hepatic or renal impairment and in patients with myasthenia gravis due to the risk of symptom aggravation.
  • Bladder outflow ob-struction because of the risk of urinary retention
  • Gastrointestinal obstructive disorders
  • uUcerative colitis and intestinal atony.
  • GI reflux
  • Those taking drugs (such as bisphosphonates) that can cause or exacerbate esophagitis.

Adverse Reactions (Side Effects):

  • General: abdominal pain, dry nasal and sinus mucous membranes, accidental injury, back pain, flu syndrome

  • Oral: Dry mouth

  • Cardiovascular: hypertension, palpitation, vasodilatation; Digestive: flatulence, GE reflux, nausea

  • Musculoskeletal: arthritis

  • Nervous: insomnia, nervousness, confusion

  • Respiratory: upper respiratory tract infection, cough, sinusitis, bronchitis, pharyngitis

  • Skin: dry skin, rash

  • Urogenital: impaired urination (hesitancy), increased post void residual volume, urinary retention, cystitis.

Dosage:

Must be swallowed whole with the aid of liquids, and must not be chewed, divided, or crushed.

May be administered with or without food.

Adults:   

  • 5 or 10 mg once daily at approximately the same time each day.
  • Dosage may be adjusted in 5-mg increments to achieve a balance of efficacy and tolerability (up to a maximum of 30 mg/day).
  • Dose adjustment may proceed at weekly intervals.

 

 


The information contained here is an abbreviated summary. For more detailed and complete information, consult the manufacturer's product information sheets or standard textbooks

Source: Operational Medicine 2001,  Health Care in Military Settings, NAVMED P-5139, May 1, 2001, Bureau of Medicine and Surgery, Department of the Navy, 2300 E Street NW, Washington, D.C., 20372-5300

This information is provided by The Brookside Associates.  The Brookside Associates, LLC. is a private organization, not affiliated with any governmental agency. The opinions presented here are those of the author and do not necessarily represent the opinions of the Brookside Associates or the Department of Defense. The presence of any advertising on these pages does not constitute an endorsement of that product or service by either the US Department of Defense or the Brookside Associates. All material presented here is unclassified.

C. 2009, 2014, All Rights Reserved

brookside associates logo

 

 

 

 

 

 

Advertise on this site